Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

You may be eligible if

• DISEASE CHARACTERISTICS:
• Healthy participants
• Deemed to be in good general health by history and physical examination
• •Resident of Guanacaste Province of Costa Rica and surrounding areas
• Must remain a resident for ≥ 6 months after the first study vaccination
• PATIENT CHARACTERISTICS:
• Age
• 18 to 25
• Performance status
• Not specified
• Life expectancy
• Not specified
• Hematopoietic
• Not specified
• Hepatic
• No history of chronic hepatitis requiring treatment
• No acute or chronic clinically significant hepatic function abnormality by physical examination or laboratory findings
• No known history of hepatitis A infection
• Renal
• No history of kidney disease requiring treatment
• No acute or chronic clinically significant kidney function abnormality by physical examination or laboratory findings
• Cardiovascular
• No acute or chronic clinically significant cardiovascular function abnormality by physical examination or laboratory findings Pulmonary
• No acute or chronic clinically significant pulmonary function abnormality by physical examination or laboratory findings Immunology
• No history of allergic disease
• No history of autoimmune disorder requiring treatment
• No history of allergic reaction (e.g., difficulty breathing) to any vaccine
• No suspected allergy or reaction likely to be exacerbated by a component of the study vaccines (e.g., 2-phenoxyethanol or neomycin)
• No hypersensitivity to latex
• No diagnosis or suspicion of any immunodeficient condition by medical history or physical examination Other
• Not pregnant or nursing
• ◦No delivery within the past 3 months
• Negative pregnancy test
• Fertile patients must use effective contraception for 30 days before, during, and for 60 days after completion of study treatment
• Able to speak or understand Spanish
• Mentally competent
• Able to undergo pelvic exam (i.e., no heavy bleeding \[menstruation or otherwise\] or heavy vaginal discharge)
• No history of cancer requiring treatment
• No history of diabetes requiring treatment
• No history of other chronic conditions requiring treatment
• No acute or chronic clinically significant neurologic function abnormality by physical examination or laboratory findings
• No other acute disease
• No fever ≥ 37.5º C
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 6 months since prior chronic administration (i.e., \> 14 days) of immune-modulating drugs
• More than 90 days since prior immunoglobulins
• More than 30 days since prior and no other concurrent investigational or non-registered vaccines
• More than 30 days since prior registered vaccines
• More than 8 days since prior routine meningococcal, hepatitis B, influenza, or diphtheria/tetanus vaccine
• No prior vaccination against hepatitis A
• No prior vaccination against human papillomavirus
• No prior monophosphoryl lipid A or AS04 adjuvant
• Chemotherapy
• Not specified
• Endocrine therapy
• More than 6 months since prior chronic administration (i.e., \> 14 days) of corticosteroids (e.g., ≥ 0.5 mg/kg/day of prednisone or equivalent)
• Concurrent inhaled or topical steroids allowed
• Radiotherapy
• Not specified
• Surgery
• No prior hysterectomy
• Other
• More than 6 months since prior chronic administration (i.e., \> 14 days) of immunosuppressants
• More than 30 days since prior and no other concurrent investigational or non-registered drugs